A fitness coach who admits GLP-1 drugs have cost him business, and a peer-reviewed BMJ editorial, agree on something the loudest voices online refuse to say: these drugs do not, by themselves, eat your muscle.
That should end the panic. Instead, it barely dents it.
The influencer narrative is seductive because it's simple. Ozempic makes people thin, thin people can look gaunt, therefore Ozempic must be melting muscle off the bone like a catabolic acid. It moves fast, it scares, and it sells whatever the poster is selling.
Layne Norton, who coaches lifters for a living, put it about as bluntly as anyone can: "GLP-1's do NOT cause muscle loss... at least not directly." His follow-up sentence is the one worth pinning up: "Despite the rhetoric on social media from wellness influencers, GLP-1's are not catabolic."
By his own account, he reportedly has a financial incentive against defending them. By his own account, "GLP-1s have probably cost me business." He's reportedly arguing against his own book.
The peer-reviewed literature lands in the same place from the opposite direction. A March 2025 editorial in BMJ Nutrition, Prevention & Health reportedly carries a title that is itself the argument: "GLP-1 receptor agonists induce loss of lean mass: so does caloric restriction."
Here are the numbers that collapse the drug-toxicity story. In caloric restriction studies, roughly 60% of weight lost is fat and about 30% is lean mass, per the BMJ editorial. Pharmacologically induced weight loss with GLP-1 drugs shows lean-mass loss of about 25% to 40%.
That is the same neighborhood. Not a drug-specific catastrophe—the ordinary, well-documented tax that any large, rapid weight loss levies, whether it comes from a diet, a surgeon, or an injection.
The BMJ authors say it plainly: since these drugs induce a calorie-restricted state, "expecting it to yield entirely different body composition outcomes than what is observed in CR studies is hard to conceive."
So the influencers are chasing the wrong culprit. The drug isn't the villain. The deficit is.
So the influencers are chasing the wrong culprit. The drug isn't the villain. The deficit is.
But this is where the reassurance has to stop, because there's a subtler mechanism that makes the GLP-1 version of that deficit genuinely worse than a coached one—and Norton names it.
These are not neutral appetite suppressants that trim intake evenly across the plate. High-protein foods happen to be the most satiating. So when appetite is chemically flattened, protein is exactly what gets crowded out first.
In Norton's words: people with suppressed appetite "are typically not choosing high protein sources since they tend to be more satiating and this can also contribute" to lean-mass loss.
The Mayo Clinic frames the same problem clinically: because the medications reduce appetite, "many people eat significantly less overall — including less protein."
That matters because the protein target during active weight loss goes up, not down. Mayo cites 1.2 to 1.6 grams per kilogram of body weight per day for people losing weight—well above the general RDA of 0.8 g/kg.
Put those together and you get the trap. The moment protein needs rise is the exact moment the drug makes protein the least appealing thing on the plate. The deficit isn't just deep and fast; it's nutritionally lopsided in the one direction that costs muscle.
There's a second complication worth being honest about, because it cuts the other way and the panic-mongers ignore it: "lean mass" is not "muscle."
DEXA scans lump skeletal muscle together with water, organs, bone, and connective tissue. Mayo lists them explicitly. So some of the "lean mass" that vanishes on a scan is fluid and other tissue, not contractile muscle.
The cardiologist Ian Neeland, reportedly quoted by diaTribe, warns that researchers use "lean mass" and "muscle mass" interchangeably, which makes clean comparison across studies genuinely hard.
There's even a plausible upside hiding in the number. diaTribe's exercise physiologist John Jakicic reportedly notes that people with obesity carry more low-quality muscle fibers and fat infiltration, and that some of the measured loss "may actually be a good adaptation from a health perspective." His refrain: "Muscle health is very different from muscle volume."
This is why strength and physical function often hold or improve even as the DEXA number drops. The scary metric and the outcome that matters can move in opposite directions.
So the truth is layered. The drug isn't catabolic. The loss is normal for the amount of weight moved. Part of the measured "muscle" loss isn't muscle. And yet the appetite mechanism does make the deficit nutritionally riskier than a supervised diet—precisely because it starves protein.
Which brings us to the part everyone agrees on and almost no one operationalizes: the fix is not a mystery.
Every credible source converges on the same two-part prescription. Protein at 1.2 to 1.6 g/kg, per Mayo. Resistance training. The Mayo brief, the Mechanick review in Obesity Reviews, and diaTribe all land on the combined approach.
Mayo: people who combine GLP-1 therapy with structured exercise "are more likely to preserve lean mass than those who do not," and aerobic work, while good for the heart, is less effective than strength training for this job.
The BMJ editorial reportedly points to the Lundgren trial as proof of concept, where lean-mass loss "was minimised by a combined approach." (The dose-response behind why resistance training does this so reliably is its own subject, covered in our companion piece.)
Norton's version is the whole argument in one line: "The choices should not be... GLP-1 or lifestyle changes. It should be: GLP-1 WITH lifestyle changes."
Here is the gap. The fix is this well-characterized. The vulnerable population is this identifiable. And the prescribing reality is a script with nothing attached.
Mayo names who is most at risk: older adults, people with low baseline muscle, the physically inactive, and women in perimenopause or postmenopause. Neeland says such patients "should be monitored much more closely" and should "think much more deeply" about whether a GLP-1 is right for them at all.
These are not edge cases.
That is the delivery model as these drugs scale to millions. Not the molecule.
If the intervention that preserves function is this well established, and the at-risk patient is this easy to spot before the first injection, then structured protein-and-resistance coaching isn't an add-on. It belongs inside the prescription.
The evidence has already converged. The honest coaches and the peer reviewers are saying the same thing. What's missing isn't the science. It's the standard of care catching up to it.